Leveraging the immense potential of Cell Penetrating Alphabodies
Partnering objectives
Complix is engaging in partnerships with other biotech and pharma companies to leverage the significant potential of its Alphabody platform, aiming to develop novel therapeutics for treatment of important diseases.
Complix is currently engaged in active collaborations and in partnering discussions relating to CPAB platform applications in oncology, immuno-oncology, autoimmunity, virology and CNS diseases.